Additional information under art. 33, par. 1, item 6 of Ordinance № 2 from 17 September 2003 of "Sopharma" AD as at 30 June 2016

1. Information about changes in accounting policies during the reporting period, the reasons for them and how they affect the financial results and equity of the issuer. The individual financial statements of Sopharma AD have been prepared in accordance with all International Financial Reporting Standards (IFRS), which comprise Financial Reporting Standards and the International Financial Reporting Interpretations Committee (IFRIC) interpretations, approved by the International Accounting Standards Board (IASB), as well as the International Accounting Standards (IAS) and the Standards Committee (IASC), which are effectively in force on 1 January 2016 and have been accepted by the Commission of the European Union.

More detailed information about the Company's accounting policies can be found at 2.1. Basis of preparation of the individual financial statements in the notes to the individual interim financial statements for the period 1 January 2016 - 30 June 2016.

2. **Information about changes in the economic group of the issuer as at 30 June 2016:** As from 16 February 2016 Mobil Line OOO is a subsidiary through Briz OOD.

As from 29 February 2016 Sopharmasi 4 EOOD is a subsidiary through Sopharma Trading AD, and as from 1 March 2016 Sopharmasi 5 EOOD is a subsidiary through Sopharma Trading AD. On 24 March Medica Balkans EOOD Romania – subsidiary through Medica AD has been liquidated and removed from the Commercial Register.

On 9 May 2016 Sopharma AD has divested its shares in its subsidiary Ivanchich and sons, Serbia.

3. Information about the results of organizational changes within the issuer, such as restructuring, sale of companies from the group, in-kind contributions from companies, rental property, long-term investments, closure of business:

On 21 January 2016 Sopharma AD submitted to the Financial Supervision Commission an agreement for termination by mutual agreement of the contract for transformation through merger between Sopharma AD, UIC 831902088, "Acquiring company" and Momina Krepost AD, Veliko Tarnovo, 23 Magistralna Str., UIC 104055543, "Acquiree". The decision to end the procedure was taken in the interest of both companies in order to safeguard their good market positions.

As at 30 June 2016, Company's tangible fixed assets included: land amounting to BGN 33,849 thousand (31 December 2015: BGN 33,251 thousand) and buildings of carrying amount BGN 78,700 thousand (31 December 2015: BGN 80,614 thousand).

Tangible fixed assets in progress as at 30 June include:

- advances granted for purchase of machinery and equipment BGN 261 thousand (31 December 2015: BGN 3,188 thousand);
- expenses on construction of a new warehouse unit BGN 12,525 thousand (31 December 2015: BGN 10,132 thousand);
- buildings reconstruction BGN 180 thousand (31 December 2015: BGN 100 thousand);
- other BGN 81 thousand (31 December 2015: BGN 82 thousand).

As at 30 June, the carrying amount of property, plant and equipment includes machinery and equipment, which have been purchased using grants under Operational Program "Development of the Competitiveness of the Bulgarian Economy" 2007 - 2013 (Note 27) as follows:

- for a new tablet production facility at the amount of BGN 7,743 thousand (31 December 2015: BGN 8,056 thousand)
- for ampule production at the amount of BGN 5,696 thousand (31 December 2015: BGN 5,861 thousand);

The amount of other assets as at 30 June 2016 includes also biological assets – Golden Chain (Laburnum anagyroides) plantation at the amount of BGN 131 thousand (31 December 2015: BGN 131 thousand).

The Company has leased tangible fixed assets with carrying amount of BGN 6,136 thousand as at 30 June 2016 to related parties (31 December 2015: BGN 6,004 thousand). In addition, tangible fixed assets at carrying amount of BGN 259 thousand were leased to third parties as at 30 June 2016 (31 December 2015: BGN 228 thousand).

The following encumbrances were constituted on Company's tangible fixed assets as at 30 June 2016 in relation with received loans:

- Land and buildings with carrying amount of BGN 22,415 thousand and BGN 60,836 thousand, respectively (31 December 2015: BGN 22,009 thousand and BGN 61,271 thousand, respectively);
- Pledges on equipment BGN 45,860 thousand (31 December 2015: BGN 38,316 thousand).

The carrying amount of the investments by company is as follows:

		30.06.2016 BGN '000	Interest %	31.12.2015 BGN '000	Interest %
Medika AD	Bulgaria	32,868	97.94	21,832	66.72
Sopharma Trading AD	Bulgaria	28,664	71.91	28,557	71.85
Briz OOD	Latvia	22,270	66.13	22,270	66.13
Unipharm AD	Bulgaria	19,448	49.99	19,448	49.99
Sopharma Ukraine	Ukraine	16,991	100.00	16,991	100.00
Biopharm Engineering AD	Bulgaria	8,384	97.15	8,384	97.15
Momina Krepost AD	Bulgaria	4,869	93.46	4,833	92.78
Vitamina AD	Ukraine	1,980	99.56	1,980	99.56
Pharmalogistica AD	Bulgaria	1,124	80.80	1,058	78.37
Sopharma Buildings REIT	Bulgaria	568	40.40	573	40.75
Sopharma Kazakhstan EOOD	Kazakstan	502	100.00	502	100.00
Electroncommerce EOOD	Bulgaria	384	100.00	384	100.00
Sopharma Warsaw EOOD	Poland	323	100.00	323	100.00
Phyto Palauzovo AD	Bulgaria	73	95.00	25	95.00
Ivanchich and sons	Serbia		<u>-</u>	5,739	51.00
Total		138,448	=	132,899	

As at 30 June 2016 the composition of investments in subsidiaries also includes the investment in the subsidiary Sopharma Poland OOD – in liquidation, Poland, which is fully impaired (31

December 2015: the investments in Sopharma Poland OOD – in liquidation, Poland was fully impaired).

Sopharma AD has direct or indirect control on the above-mentioned companies.

- 4. Opinion of the governing body regarding the feasibility of the published estimates of the results for the current financial year, taking into account the results of the current quarter as well as information on the factors and circumstances that will affect the achieving of the projected results for at least the next quarter no update of the forecast results.
- 5. For public companies data on persons holding directly or indirectly at least 5 percent of the voting rights of the General Meeting at the end of the quarter, and changes in ownership of those voting rights since the end of the preceding quarter;

SHAREHOLDERS	Number of shares /%/ 30 June 2016	Number of shares /%/ 31 December 2015
"Donev Investments Holding" AD,	33 336 052 /24,73% /	33 330 426 /24,73%/
EIK 831915121,		
Sofia, Positano Str. № 12		
"Telecomplect Invest" AD,	27 056 752 /20,07%/	26 056 752 /20,07%/
EIK 201653294,		
Sofia, Slaveikov Square № 9		
"Rompharm Company" OOD	24 313 355 /18,04%/	24 313 355 /18,04%/
UID 200732874		
Sofia, Mladost residential complex,		
Boian Damianov Str. 7, office 3		

6. For public companies - data on persons holding directly or indirectly at least 5 percent of the voting rights of the General Meeting at the end of the quarter, and changes in ownership of those voting rights since the end of the preceding quarter:

Members of the Board of Directors	Number of shares 30 June 2016	Number of shares 31 December 2015		
1. Ognian Ivanov Donev	0	0		
2. Vessela Liubenova Stoeva	0	0		
3. Andrey Liudmilov Breshkov	0	0		
4. Ognian Kirilov Palaveev	120 430	102 585		
5. Alexander Viktorov Chaushev	97 976	97 976		

- 7. Information on pending judicial, administrative or arbitration proceedings relating to liabilities or receivables amounting to at least 10 percent of the equity of the company none.
- 8. Information on loans granted by the issuer or their subsidiary, provided guarantees or commitments to a single person or a subsidiary thereof, including to related persons with indication of the nature of the relationship between the issuer and the person, the amount of the outstanding principal, the interest rate, the maturity, the size of commitment, the terms and conditions.

The *long-term receivables from related parties* at 30 June include:

	BGN '000	BGN '000
Long-term loans granted	11,858	20,213
Long-term rental deposit granted	231	292
Total	12,089	20,505

The long-term loans are granted to companies related through key management personnel.

The terms and conditions of the long-term loans granted to related parties are as follows:

Currency Contracted amount		Maturity	Interest %	30.0	06.2016	31.12.2015		
	'000			BGN'000	BGN'000 Including interest	BGN'000	BGN'000 Including interest	
to companies relate	ed through key	management p	ersonnel					
EUR	16,177	01.12.2018	5.00%	10,860	177	13,074	18	
EUR	3,272	01.12.2018	5.00%	-	-	7,139	739	
to subsidiaries EUR	500	01.03.2019	6.60%	998	20	-	-	
					197		757	
				11,858		20,213		

The long-term loans granted to related parties are intended to support the financing of these companies' activities under common strategic objectives. They are secured by pledges on securities (shares).

The long-term deposit receivable is from a company related through key management personnel under a concluded rental contract for administrative offices with validity term on 1 August 2022.

Receivables from related parties include:

Receivables from related parties include:

Receivables from related parties include:	30.06.2016 BGN '000	31.12.2015 BGN '000
Receivables from subsidiaries	77,170	59,515
Impairment of uncollectable receivables	(2,975)	(3,025)
	73,694	56,490
Receivables from companies related through key managing personnel	21,808	21,545
Impairment of uncollectable receivables	(328)	-
	21,480	21,545
Receivables from companies related through a main shareholders	511	
Total	96,186	78,035
The receivables from related parties by type are as follows:		
	30.06.2016 BGN '000	31.12.2015 BGN '000

Receivables on sales of finished products and materials	55,239	50,847
Impairment of uncollectable receivables	(848)	(1,062)
	54,391	49,785
Trade loans granted	34,821	30,213
Impairment of uncollectable receivables	(2,467)	(1,963)
	32,354	28,250
Dividends	8,941	-
Advance payments	500	
Total	96,186	78,035

The receivables on sales are interest-free and BGN 36,796 thousand of them are denominated in BGN (31 December 2015: BGN 28,364 thousand) and in EUR – BGN 17,595 thousand (31 December 2015: BGN 21,421 thousand).

The receivables from a subsidiary with principal activities in the field of trade in pharmaceuticals were the most significant and amounted to BGN 36,419 thousand as at 30 June 2016 or 66,96% of all receivables on sales of finished products and materials to related parties (31 December 2015: BGN 27,103 thousand – 54,44%).

Loans granted to related parties by type of related party are as follows:

	30.06.2016 BGN '000	31.12.2015 BGN '000
Receivables from companies related through key managing personnel Impairment of trade loans	21,804 (328)	21,545
	21,476	21,545
Subsidiaries	13,005	8,668
Impairment of trade loans	(2,127)	(1,963)
_	10,878	6,705
Total	32,354	28,250

The terms and conditions of the loans granted to related parties are as follows:

Currency	Contracted amount	Maturity	Interest %	30.06.2016		31.12	2.2015					
	'000			BGN'000	BGN'000	BGN'000	BGN'000					
					including interest		including interest					
to companies	to companies related through key managing personnel											
EUR	8,113	31.12.2016	4.50%	8,362	_	7,982	146					
EUR	12,731	31.12.2016	4.50%	8,237	173	8,310	26					
BGN	6,000	31.12.2016	5.50%	4,763	128	4,636	1					
BGN	190	31.12.2016	5.50%	114	2	114	-					
BGN	1,300	31.12.2016	5.50%	-	-	503	42					
to subsidiarie	S											
BGN	7,667	31.12.2016	5.50%	5,741	99	1,568	42					
EUR	2,770	31.12.2016	6.10%	5,087	-	5,087	-					
BGN	600	31.12.2016	5.50%	50		50						
				32,354	402	28,250	257					

The short-term loans granted to related parties are intended to support the financing of these companies' activities under common strategic objectives. They are secured by pledges on corporate shares and securities (shares).

The *payables to related parties* refer to:

The payables to related parties refer to:

	30.06.2016 BGN '000	31.12.2015 BGN '000
Payables to main shareholding companies	4,271	89
Payables to companies related through key managing personnel	812	1,702
Payables to companies related through main shareholder	658	411
Payables to subsidiaries	172	868
Total	5,913	3,070

The trade payables to related parties are regular and are not additionally secured by the Company. The payables in Bulgarian Levs amount to BGN 5,890 thousand (31 December 2015: BGN 3,051 thousand), in EUR – none (31 December 2015: BGN 10 thousand), in PLN – BGN 23 thousand (31 December 2015: BGN 9 thousand).

The Company is a co-debtor under received bank loans, issued bank guarantees and concluded lease agreements as well as a guarantor before banks and suppliers of the following companies:

Company	Maturity period	Currency	Contracted amount		Amount of the guarantee as at
			original currency	BGN'000	30.06.2016 BGN'000
	2016-2021				
Sopharma Trading AD Sopharma Properties	г.	EUR	53,739	105,104	85,185
REIT	2024 г. 30.09.2016	EUR	22,619	44,240	31,806
Sopharma Trading AD	г 22.07.2016	BGN	14,732	14,732	14,104
Sopharma Ukraine AD	г 22.07.2016	EUR	7,000	13,691	7,521
Vitamini OAO	г 16.04.2023	EUR	7,000	13,691	5,818
Biopharm Engineering AD	Γ	BGN	4,250	4,250	1,415
Veta Pharma AD	13.12.2016 г	BGN	1,000	1,000	471
Mineralcommerce AD	2017 г. 27.06.2016	EUR	150	294	236
Mineralcommerce AD	Γ	BGN	250	250	196
Pharmaplant AD	2019 г.	BGN	1,083	1,083	236
Total					146,988

The Company has provided the following collateral under loads, received from related parties, in favor of banks:

- a) under loans received by subsidiaries:
- mortgages of real estate BGN 10,470 thousand (31 December 2015: BGN 10,572 thousand);
- special pledges on:
 - machinery and equipment BGN 11,323 thousand (31 December 2015: BGN 11,640 thousand);
 - inventories BGN 17,000 thousand (31 December 2015: BGN 17,000 thousand);
 - trade receivables BGN 11,735 thousand (31 December 2015: BGN 11,735 thousand).
- b) under loans received by companies related through key managing personnel:
- mortgages of real estate BGN 1,119 thousand (31 December 2015: BGN 1,119 thousand);
- c) under loans received by third parties:

•	special thousan	 on	inventories	_	BGN	2,623	thousand	(31	December	2015:	BGN	2,623
									Ognian Do Executive			